Forskning ved Københavns Universitet - Københavns Universitet

Forside

Cancer systems biology: Harnessing off-target effects

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

Standard

Cancer systems biology : Harnessing off-target effects. / Saginc, Gaye; Voellmy, Franziska; Linding, Rune.

I: Nature Chemical Biology, Bind 13, Nr. 12, 21.11.2017, s. 1204-1205.

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

Harvard

Saginc, G, Voellmy, F & Linding, R 2017, 'Cancer systems biology: Harnessing off-target effects', Nature Chemical Biology, bind 13, nr. 12, s. 1204-1205. https://doi.org/10.1038/nchembio.2519

APA

Saginc, G., Voellmy, F., & Linding, R. (2017). Cancer systems biology: Harnessing off-target effects. Nature Chemical Biology, 13(12), 1204-1205. https://doi.org/10.1038/nchembio.2519

Vancouver

Saginc G, Voellmy F, Linding R. Cancer systems biology: Harnessing off-target effects. Nature Chemical Biology. 2017 nov 21;13(12):1204-1205. https://doi.org/10.1038/nchembio.2519

Author

Saginc, Gaye ; Voellmy, Franziska ; Linding, Rune. / Cancer systems biology : Harnessing off-target effects. I: Nature Chemical Biology. 2017 ; Bind 13, Nr. 12. s. 1204-1205.

Bibtex

@article{01167e764bfc4fe0b015995f80f6c3ab,
title = "Cancer systems biology: Harnessing off-target effects",
abstract = "The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action",
author = "Gaye Saginc and Franziska Voellmy and Rune Linding",
year = "2017",
month = "11",
day = "21",
doi = "10.1038/nchembio.2519",
language = "English",
volume = "13",
pages = "1204--1205",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "nature publishing group",
number = "12",

}

RIS

TY - JOUR

T1 - Cancer systems biology

T2 - Harnessing off-target effects

AU - Saginc, Gaye

AU - Voellmy, Franziska

AU - Linding, Rune

PY - 2017/11/21

Y1 - 2017/11/21

N2 - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action

AB - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action

U2 - 10.1038/nchembio.2519

DO - 10.1038/nchembio.2519

M3 - Letter

C2 - 29161245

AN - SCOPUS:85034819030

VL - 13

SP - 1204

EP - 1205

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 12

ER -

ID: 186635336